Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-24T05:49:11.206Z Has data issue: false hasContentIssue false
  • English
  • Français

Developing Medicines in Line with Global Public Health Needs: The Role of the World Health Organization

Published online by Cambridge University Press:  25 March 2011

TIKKI PANG
Get access Rights & Permissions [Opens in a new window]

Extract

“I want my leadership to be judged by the impact of our work on the health of two populations: women and the people of Africa.” This is how Dr. Margaret Chan, the current Director-General of the World Health Organization (WHO), described her leadership mission. The reason behind this mission is evident. Women and girls constitute 70% of the world’s poor and 80% of the world’s refugees. Gender violence against women aged 15–44 is responsible for more deaths and disability than cancer, malaria, traffic accidents, and war. An estimated 350,000 to 500,000 women still die in childbirth every year. The negative health implications of absolute poverty are worst in Sub-Saharan Africa and South Asia. Hence, Chan aims to have the biggest impact on the world’s poorest people.

Type
Symposium on Global Bioethics
Information
Cambridge Quarterly of Healthcare Ethics , Volume 20 , Issue 2 , April 2011 , pp. 290 - 297
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. WHO. Agenda; available at http://www.who.int/about/agenda/en/index.html (last accessed 28 Jun 2010).

2. Oxfam Australia. Gender equality; available at http://www.oxfam.org.au/explore/gender-equality (last accessed 28 Jun 2010).

3. Partnership for Maternal, Newborn & Child Health. Countdown to 2015 MNCH Landscape Analysis press release; available at http://www.who.int/pmnch/media/press_materials/pr/2010/20100413_countdownmap/en/ (last accessed 28 Jun 2010).

4. WHO. Constitution; available at http://www.who.int/governance/eb/constitution/en/index.html (last accessed 28 Jun 2010).

5. Leisinger, KM, Schmitt, KM. Access to healthcare and the pharmaceutical sector. Cambridge Quarterly of Healthcare Ethics, this issue, 309–325.Google Scholar

6. Ezzati, M, Lopez, AD, Rodgers, A, Vander, Hoorn S, Murray, CJL, and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347–60.CrossRefGoogle ScholarPubMed

7. WHO. Background on the global strategy and plan of action on public health, innovation and intellectual property; available at http://www.who.int/phi/implementation/phi_globstat_action/en/index.html (last accessed 28 Jun 2010).

8. World Bank. 2010 World Development Indicators. Washington, DC: World Bank; 2010, at p. 289; available at http://data.worldbank.org/sites/default/files/wdi/complete.pdf (last accessed 28 Jun 2010).Google Scholar

9. Selgelid, M, Sepers, EM. Patents, profits, and the price of pills: Implications for access and availability. In: Illingworth, P, Schuklenk, U, Cohen, JC, eds. The Power of Pills: Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing Policies. London: Pluto Press; 2006:153–63Google Scholar, at p. 153.

10. Chirac, P, Torreele, E. Global framework on essential health R&D. Lancet 2006;367:1560–61.CrossRefGoogle Scholar

11. Schroeder, D. Does the pharmaceutical sector have a coresponsibility for the human right to health? Cambridge Quarterly of Healthcare Ethics, this issue, 298–308.Google Scholar

12. See note 11, Schroeder 2010.

13. Medicines for Malaria Venture Web site; available at http://www.mmv.org/about-us (last accessed 28 Jun 2010).

14. Medicines for Malaria Venture. Pyramax® dossier submitted to EMA; available at http://www.mmv.org/achievements-challenges/achievements/pyramax%C2%AE-dossier-submitted-ema (last accessed 28 Jun 2010).

15. Foundation for Innovative New Diagnostics Web site; available at http://www.finddiagnostics.org/about/ (last accessed 28 Jun 2010).

16. See note 15, FIND Web site.

17. WHO. Public Health Innovation and Intellectual Property; available at http://www.who.int/phi/en/ (last accessed 28 Jun 2010).

18. WHO Resolution WHA61.21, 2008; available at http://apps.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf (last accessed 28 Jun 2010).

19. WHO. Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property, 2008; available at http://www.who.int/phi/implementation/phi_globstat_action/en/print.html (last accessed 28 Jun 2010).

20. See note 18, WHA61.21.

21. Expert Working Group on Research and Development Financing. Public Health, Innovation and Intellectual Property: Report of the Expert Working Group on Research and Development Financing. Geneva: World Health Organization; 2009, at p. 16. Available at http://apps.who.int/gb/ebwha/pdf_files/EB126/B126_6Add1-en.pdf (last accessed 28 Jun 2010).

22. Innocentive Web site; available at http://www.innocentive.com/about-us-open-innovation.php (last accessed 28 Jun 2010).

23. See note 21, Expert Working Group on Research and Development Financing 2009:14.

24. See note 21, Expert Working Group on Research and Development Financing 2009:19.

25. Pogge, T. The Health Impact Fund: Boosting pharmaceutical innovation without obstructing free access. Cambridge Quarterly of Healthcare Ethics 2009;18(1):78–86.CrossRefGoogle ScholarPubMedPogge, T. The Montréal Statement on the Human Right to Essential Medicines. Cambridge Quarterly of Healthcare Ethics 2007;16:97–108.CrossRefGoogle ScholarPubMed